When GLP-1 Medications Cause Skin Pain: A Side Effect Worth Knowing About
- JoBeth Augustyniak, DO
- 11 minutes ago
- 6 min read
A real patient encounter that led me down a research rabbit hole — and what I found.
By Dr. JoBeth Augustyniak, DO, AOBFP | Attune Direct Care & Wellness | Metabolic Health
Recently, I had a patient who made the decision to restart her GLP-1 medication after regaining weight following a period off it. She is otherwise healthy — no major red flags in her history, no new medications, nothing obvious that should have changed. But within a few weeks of restarting, she came to me with a complaint I had never heard associated with GLP-1 therapy before.
Her skin hurt to touch. Not just mildly uncomfortable — genuinely painful. The upper arms, the back, the thighs. Light contact. Clothing. A gentle brush against something. All of it was triggering a pain response that was disproportionate to what was causing it.
As a physician, my first instinct was to think through the differential. Neurological conditions. Autoimmune disorders. Vitamin deficiencies — B12, D, folate. Small fiber neuropathy. Things that actually cause that kind of symptom. I started down that road because it was the responsible thing to do, and I still plan to work through those possibilities with her systematically.
But in the process of researching, I found something that stopped me in my tracks: this symptom has a name, it is associated with GLP-1 medications, and it is significantly under-reported and under-recognized in clinical practice. It is called dysesthesia — and I want to share what I found, because if it happened to my patient, it is probably happening to yours.
What Is Dysesthesia?
Dysesthesia is the medical term for an abnormal, often unpleasant skin sensation — pain, burning, tingling, or extreme sensitivity that is not proportional to what caused it. A specific variant called allodynia describes pain triggered by stimuli that are normally completely harmless: light clothing contact, air movement, a gentle touch.
My patient's description — pain to touch on the upper arms, back, and thighs — fits this pattern almost exactly. And the bilateral, symmetrical distribution is characteristic. This is not a localized injury or irritation. It is a nervous system phenomenon.
What the Research Shows
Dysesthesia has been documented across multiple GLP-1 receptor agonist medications, and the data reveals a clear and important pattern: the higher the dose, the higher the risk.
Semaglutide (Wegovy / Ozempic)
At the standard obesity dose of 2.4 mg, dysesthesia was reported in approximately 2.1% of participants in clinical trials, versus 1.2% on placebo. Not common, and rarely severe enough to stop the medication. But at the experimental high dose of 7.2 mg studied in the STEP UP trial, that number climbed to 22.9% — nearly one in four patients. That is not a statistical footnote. That is a clinically meaningful signal of a strongly dose-dependent side effect.
Tirzepatide (Zepbound / Mounjaro)
Standard clinical doses (5 mg to 15 mg) showed very low rates in the SURMOUNT trials — 0.2% to 0.4%. However, post-market pharmacovigilance data from global reporting systems like VigiBase tells a more complex story: real-world reports of allodynia following dose step-ups are rising. Controlled trials often undercount what patients actually experience in practice, and this appears to be one of those cases.
Retatrutide (Experimental Triple Agonist)
Not yet FDA-approved, but worth understanding. At mid-range doses in Phase 2 trials, 7% of patients reported cutaneous hypersensitivity. At the maximum 12 mg dose in Phase 3 TRIUMPH-4 safety data, that figure rose to 20.9% — compared to just 0.7% on placebo. The hypothesis is that adding glucagon receptor activation to the GLP-1/GIP dual mechanism uniquely alters metabolic-neural sensory pathways in a way that amplifies this risk.
Why Does This Happen? The Leading Theories
There is no single established mechanism yet, but several well-supported hypotheses help explain what we are seeing:
GLP-1 Receptors on Peripheral Sensory Nerves
GLP-1 receptors are not confined to the gut and pancreas. They are present on peripheral sensory neurons — including the dorsal root ganglia and unmyelinated C-fibers that carry pain and temperature signals. Overstimulation of these receptors, particularly at higher doses, may cause misfiring — phantom pain signals without a real physical cause.
Rapid Metabolic Shifts
Significant or rapid changes in blood glucose can trigger what is sometimes called treatment-induced neuropathy. When the metabolic environment shifts quickly — especially in someone who was previously hyperglycemic — nerve cell hydration and axon metabolism can be temporarily disrupted, producing burning, tingling, or hypersensitivity.
Loss of Subcutaneous Fat
Rapid weight loss depletes the cushioning layer of fat directly beneath the skin. That layer protects the microscopic nerve endings embedded in the dermis from mechanical pressure and friction. As it thins quickly, those nerve endings become more exposed — lowering the threshold for pain signals from stimuli that were previously unremarkable.
This Is Where Clinical Judgment Matters
I want to be clear about something: finding this information does not mean I am closing the book on my patient's workup. The responsible approach is to hold both possibilities at once.
I will still check:
Vitamin B12 — especially relevant if she has any history of metformin use or dietary restriction
Vitamin D — a common deficiency in this region, and worth ruling out as a contributing factor
Folate and thiamine — part of a thorough neuropathy screen
Thyroid function — hypothyroidism can produce paresthesias and is easy to miss
Inflammatory markers and ANA — to take a reasonable pass at autoimmune causes
Blood glucose trends — to assess whether rapid metabolic improvement may be playing a role
If those workup results come back unremarkable, dysesthesia from her restarted GLP-1 becomes the leading diagnosis by exclusion — and a very actionable one.
What Can Be Done About It
The good news is that this side effect is considered manageable, and the medication discontinuation rate due to dysesthesia is under 1%. Most cases resolve on their own over a few months, or clear up quickly with modest dosing adjustments.
Dosing Strategies to Try First
A dose freeze: Rather than continuing to escalate on schedule, holding the current dose for an additional 4 to 8 weeks gives the nervous system time to adapt. Many patients find symptoms fade without any further intervention.
A temporary dose reduction: Stepping back to the previous dose level often resolves symptoms within days. Once things have settled, a slower re-escalation can be attempted.
A brief pause: In cases where symptoms are significantly impacting daily life or sleep, a temporary hold on the medication may be the most compassionate short-term approach — particularly if the workup is still pending.
Symptomatic Management in the Meantime
Loose, soft, seamless clothing in natural fabrics (cotton, bamboo) reduces friction-triggered allodynia
Lukewarm — not hot — showers, as heat can excite sensitized nerve endings
Fragrance-free, gentle cleansers to avoid adding chemical irritation on top of nerve sensitivity
Over-the-counter 4% lidocaine cream for localized areas of most intense discomfort
If Symptoms Persist
For rare cases that do not respond to dosing adjustments and the workup has excluded other causes, a short course of low-dose gabapentin can be considered to calm peripheral nerve misfiring. This is not a first-line move, but it is a reasonable option when staying on the GLP-1 is clinically important and nothing else has provided relief.
The Bigger Picture
GLP-1 medications are among the most powerful tools we have had in metabolic medicine in a generation. They are also complex, dose-sensitive drugs with a side effect profile that is still being characterized in real-world practice — especially at higher doses and in patients who stop and restart.
My patient came to me with a symptom that I had not encountered before in this context. That is not a failure of her care — it is simply the reality of practicing medicine with medications that are still being understood. What matters is that I did not dismiss it, I did not immediately assume the worst, and I now have a framework for approaching it thoughtfully: rule out the reversible causes, address the medication variable, treat the discomfort in the meantime, and stay in the conversation with her as we figure it out together.
That is what relationship-based care is for. Not every answer is in the textbook yet. Sometimes you research, stay humble, and take it one step at a time with your patient beside you.
On a GLP-1 medication and have questions about side effects?
Attune members can message Dr. JoBeth directly through the patient portal — no appointment needed for conversations like this one. Not yet a member? Book a free Discovery Call at attunedirectcare.com to learn whether membership-based, relationship-driven primary care might be the right fit for you.
Medical Disclaimer
This post is for educational purposes and reflects my clinical thought process in a real patient encounter. It is not a substitute for individualized medical advice. If you are experiencing new or concerning symptoms, please contact your physician. Attune Direct Care members can reach Dr. Augustyniak directly through the member portal.
Comments